Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Volixibat · SHP626

Small molecule · Inhibitor of Ileal Bile Acid Transporter (IBAT) (SLC10A2) · developed by Mirum Pharmaceuticals

Phase 2 Most advanced trial
MIRM Developer
2 Registered trials

What is Volixibat?

Volixibat is a small-molecule inhibitor of the ileal bile acid transporter (IBAT). It is studied in primary biliary cholangitis and non-alcoholic steatohepatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SHP626
Drug type
Small molecule
Targets
Ileal Bile Acid Transporter (IBAT) (SLC10A2)
Mechanism
Inhibitor of Ileal Bile Acid Transporter (IBAT) (SLC10A2)
Pathways
bile acid metabolism
Therapy area
Gastroenterology
Developer
Mirum Pharmaceuticals, Inc. (MIRM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
X2JZ0451H8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05050136 Phase 2 Primary Biliary Cholangitis Active not recruiting MIRM
NCT02787304 Phase 2 Non-Alcoholic Steatohepatitis Terminated MIRM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

PBCPrimary Biliary CholangitisNon-Alcoholic Steatohepatitis

Other drugs acting on SLC10A2

Maralixibat FDA approved

More from Mirum Pharmaceuticals

Cholic Acid FDA approved Maralixibat FDA approved Brelovitug Phase 2/3 MRM-3379 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MIRM page.

Follow MIRM, the company behind Volixibat

See MIRM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MIRM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.